Target intelligence / Profile preview

HLA-A*03:01–CD45 peptide complex (None established; typically referred to as peptide/HLA-A*03:01 complex)

Target
None established; typically referred to as peptide/HLA-A*03:01 complex
Molecular classification
Major histocompatibility complex class I molecule, Peptide–MHC complex, Receptor (HLA class I acts as ligand for TCR), Immune checkpoint (broadly, as MHC-I molecules present antigens to T cells)
01

Overview

The HLA-A*03:01–CD45 peptide complex consists of a CD45-derived peptide presented by the HLA-A*03:01 molecule on the cellular surface. HLA-A*03:01 is a class I MHC molecule that binds intracellular peptides and displays them for recognition by CD8+ T cell receptors. Specific peptide/HLA-A*03:01 complexes are central to immune discrimination in cancer, infection, and autoimmunity. Their therapeutic utility arises in cancer immunotherapy, where T cell receptors or engineered antibodies can selectively target tumor cells displaying neoantigenic peptides in this context, leading to immune-mediated cell death. The molecular specificity, structural stability, and clinical relevance depend on both the peptide sequence and the HLA allele, making this complex a key immunological target in personalized medicine and immuno-oncology.

Other names
Peptide/HLA-A*03:01 complexHLA-A*03:01–peptide complexHLA class I peptide complex (specific for A*03:01)MHC-I CD45 peptide complex
02

Mechanism of action

Recognition by engineered T cell receptors (TCR) leading to T cell activation and cytotoxicity against peptide-presenting cells Binding by TCR-mimic antibodies, facilitating immune depletion of target cells

03

Biological functions

Antigen presentationImmune response (activation of CD8+ T cells)Immune surveillanceCell recognition
04

Disease associations

Cancer (used as tumor neoantigen for immunotherapy, e.g., mutated protein fragments including CD45-derived peptides)Infection (presented peptide can derive from viral proteins)Autoimmune disease (misrecognition may contribute)
05

Safety considerations

Off-target toxicity (potential presentation of similar peptides on normal cells)Immunogenicity and potential for autoimmunity due to cross-reactivityHLA restriction (only patients with HLA-A*03:01 benefit)
06

Interacting drugs

TCR-engineered T cells (adoptive cell therapy)

1 more in the full profile.

07

Biomarkers

Presence of HLA-A*03:01 allele (patient selection for immunotherapy)Expression of CD45-derived or other tumor-specific peptides in the context of HLA-A*03:01TCR repertoire profiling (for monitoring immunogenic responses)

Beyond the preview

Go deeper on HLA-A*03:01–CD45 peptide complex (None established; typically referred to as peptide/HLA-A*03:01 complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLA-A*03:01–CD45 peptide complex (None established; typically referred to as peptide/HLA-A*03:01 complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call